06th week of 2022 patent applcation highlights part 9 |
Patent application number | Title | Published |
20220040110 | Formulations and Methods for Contemporaneous Stabilization of Active Proteins During Spray Drying and Storage - A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compostions related to plasma dried by the methods of the present invention. | 2022-02-10 |
20220040111 | GEL-INDUCIBLE COMPOSITION FOR PET ADMINISTRATION ASSISTANCE - Provided is a gel-inducible composition for pet administration assistance. The gel-inducible composition for pet administration assistance has a viscosity sufficient to adhere to the ceiling of the pet's mouth by containing an oil component alone or containing a high concentration of a viscosity-adjusting agent in the oil component. When a powdered prescription drug is mixed with the composition, there is no layer separation between the composition and the powdered drug occurs, and when the mixture is scooped up with a finger and applied to the ceiling of the pet's mouth, the mixture completely adheres to the ceiling of the pet's mouth and the drug is naturally absorbed when the composition component melts. Thus, the composition makes it possible to administer the prescription drug at an appropriate dosage. | 2022-02-10 |
20220040112 | FORMULATIONS OF TRIPHENYL CALCILYTIC COMPOUNDS - The present disclosure provides tablet formulations including a triphenyl calcilytic compound for the treatment of autosomal dominant hypocalcemia (ADH), where the compound is represented by formula (I): | 2022-02-10 |
20220040113 | SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - Described herein are synthetic progestogens, such as 6β,7β15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use. | 2022-02-10 |
20220040114 | Delayed Release Methylphenidate Compositions - The present disclosure provides programmable osmotic-controlled oral compositions providing delayed extended release of a therapeutically acceptable amount of methylphenidate hydrochloride. The programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, and volume of gastric fluid. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm that matches the circadian rhythm of an individual being treated to optimize therapeutic outcome and minimize side effects. | 2022-02-10 |
20220040115 | PHARMACEUTICAL COMPOSITIONS AND DELIVERY SYSTEMS FOR PREVENTION AND TREATMENT OF CANDIDIASIS - Pharmaceutical composition and delivery system for prevention and treatment of candidiasis featuring a composition of thymol oil, eugenol oil, and/or carvacrol oil encapsulated in microcapsules, with the microcapsules embedded in a medicated microbial cellulosic matrix. The cellulosic matrix may in turn be embedded in or form a conveyance material, such as a panty liner, a mucoadhesive patch, or chewing gum. | 2022-02-10 |
20220040116 | CHOLESTOSOME VESICLES FOR INCORPORATION OF MOLECULES INTO CHYLOMICRONS - The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject. | 2022-02-10 |
20220040117 | ANELLOSOMES FOR DELIVERING INTRACELLULAR THERAPEUTIC MODALITIES - This invention relates generally to anellosomes and compositions and uses thereof. | 2022-02-10 |
20220040118 | GOLD NANO-DELIVERY SYSTEM FOR PAIN AND CANCER THERAPY - The present invention relates to development of a novel cannabinoid-based gold nanoparticle drug delivery system for intravenous or localized administration of cannabinoid drugs. More specifically, the gold nanoparticles with a specific size range are conjugated with various cannabinoid molecules (CBD and THC molecules) to synthesize a stable and biocompatible nano-delivery system suitable for both localized and intravenous administration. | 2022-02-10 |
20220040119 | GOLD NANO-DELIVERY SYSTEM FOR PAIN AND CANCER THERAPY - The present invention relates to development of a novel cannabinoid-based gold nanoparticle drug delivery system for intravenous or localized administration of cannabinoid drugs. More specifically, the gold nanoparticles with a specific size range are conjugated with various cannabinoid molecules (CBD and THC molecules) to synthesize a stable and biocompatible nano-delivery system suitable for both localized and intravenous administration. | 2022-02-10 |
20220040120 | PHARMACEUTICAL FORMULATIONS CONTAINING GABOXADOL FOR THERAPEUTIC TREATMENT - Pharmaceutical formulations containing gaboxadol or a pharmaceutically acceptable salt thereof and methods of treating essential tremors, Tourette syndrome or Fragile X syndrome are provided. Pharmaceutical formulations herein include transdermal formulations and modified release dosage forms. In embodiments, a modified release dosage form includes an orally disintegrating dosage form. In embodiments, a modified release dosage form includes an extended release dosage form. In embodiments, a modified release dosage form includes a delayed release dosage form. In embodiments, a modified release dosage form includes a pulsatile release dosage form. | 2022-02-10 |
20220040121 | PATCH - The objective of the present invention is to provide a local anesthetic agent-containing patch having a skin permeability, cohesion force and adhesive property practical as a pharmaceutical product. The patch of the present invention is characterized in comprising a backing layer, and an adhesive layer on the backing layer, wherein the adhesive layer comprises at least a local anesthetic agent, a thermoplastic elastomer, a higher fatty acid ester, and a polyol fatty acid monoester, and a ratio of the higher fatty acid ester to 100 mass parts of the thermoplastic elastomer is 25 mass parts or more and 200 mass parts or less. | 2022-02-10 |
20220040122 | COMPOSITION FOR ALLERGY PREVENTION, ATOPIC DERMATITIS ALLEVIATION OR SKIN REGENERATION, CONTAINING, AS ACTIVE INGREDIENT, UNDECANE OR UNDECANAL - The present invention relates to a composition for allergy prevention, atopic dermatitis alleviation or skin regeneration, containing, as an active ingredient, undecane or undecanal and, more specifically, to a composition for preventing or treating allergic disease or atopic dermatitis and a composition for healing skin wound or promoting skin regeneration, both of which contain, as an active ingredient, at least one selected from a group consisting of undecane, undecanal or pharmaceutically acceptable salts thereof. | 2022-02-10 |
20220040123 | ANTI-HELICOBACTER FOOD COMPOSITION COMPRISING BETA-CARYOPHYLLENE | 2022-02-10 |
20220040124 | COMPOSITIONS COMPRISING CBD FOR TREATING MENTAL DISORDERS - The present invention discloses compositions comprising CBD and several herbal extract and use thereof in treatment of mental disorders such as Attention Deficit Hyperactivity disorder (ADHD) and Post Traumatic Stress Disorder (PTSD). | 2022-02-10 |
20220040125 | PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIDIOL AND BETA-CARYOPHYLLENE AND METHODS FOR THEIR USE - The disclosure describes compositions comprising beta-caryophyllene (BCP) and cannabidiol (CBD). The disclosure also describes compositions which further introduce low levels of THC. The disclosure further describes methods of making and using said compositions, including for the treatment of chronic pain, neurological disorders including epilepsy, addiction and inflammatory skin conditions. The disclosure further describes the use of fluorinated-CBD derivatives for treating inflammatory skin conditions. | 2022-02-10 |
20220040126 | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders - The present disclosure is directed to methods of treating a steatosis-associated disorder and methods of treating a cytoplasmic glycogen storage disorder, including glycogen storage disease I, glycogen storage disease III, glycogen storage disease IV, and/or conditions associated with a PRKAG2 mutation, by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage. Methods of treating a cytoplasmic glycogen storage disorder by administering a lysosomal enzyme and a second therapeutic agent are also described. Other embodiments are directed to methods of treating a cytoplasmic glycogen storage disorder by administering a therapeutic agent as an adjunctive therapy to lysosomal enzyme replacement therapy. | 2022-02-10 |
20220040127 | COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS - The invention features compositions, methods, and kits containing (i) one or more cysteamine precursor compounds convertible to cysteamine in vivo, and (ii) optionally agents to enhance that conversion, formulated to produce a spectrum of pharmacokinetic profiles of cysteamine that can be tailored to individual patients and diseases. The invention also features varying modes of administration of the therapeutic substances in the treatment of cystinosis and other cysteamine sensitive disorders. In particular, formulations combining active ingredient(s) with pharmaceutical excipients that permit sustained cysteamine plasma concentrations are featured. | 2022-02-10 |
20220040128 | METHODS OF ADMINISTERING GAMMA-HYDROXYBUTYRATE COMPOSITIONS WITH DIVALPROEX SODIUM - Oral pharmaceutical compositions of gamma-hydroxybutyrate (GHB) suitable for concomitant administration with a dose of divalproex sodium (DVP) without materially altering the dosage amount of either drug are provided. Also provided are therapeutic uses of the compositions for the treatment of one or more symptoms of narcolepsy. | 2022-02-10 |
20220040129 | TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH RENAL INSUFFICIENCY - Disclosed herein are methods of for treating hyperammonemia in a patient having renal impairment, comprising administering carglumic acid to said patient at a reduced daily dosage. | 2022-02-10 |
20220040130 | METHODS FOR TREATING FAMILIAL ADENOMATOUS POLYPOSIS - Provided are methods for preventing or delaying the need for surgical intervention in a patient having familial adenomatous polyposis (FAP) and an at least partially intact lower gastrointestinal tract. Also provided are methods for preventing or delaying the formation of neoplasia and/or cancer in a patient having FAP. The methods comprise administering an effective amount of a pharmaceutical therapy that comprises eflornithine and sulindac to a patient having FAP and an intact lower gastrointestinal tract. | 2022-02-10 |
20220040131 | PROPHYLACTIC AGENT FOR SPONTANEOUS CANCERS - A prophylactic agent for spontaneous cancer may contain a plant fermentation product as a mixture of (a) to (g), fermentation products of: (a) barley, black soybean, red rice, black rice, adzuki bean, adlay, Japanese barnyard millet, foxtail millet, and/or proso millet; (b) mandarin orange, grape, apple, | 2022-02-10 |
20220040133 | ORAL THERAPY USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID - The invention provides methods and compositions for treating a disease or disorder by orally administering to a patient in need thereof 6,8-bis-benzylthio-octanoic acid or a pharmaceutically acceptable salt thereof, optionally in combination with a second therapeutic agent. | 2022-02-10 |
20220040134 | ELECTROPHILES AND ELECTROPHILE PRO-DRUGS AS RAD51 INHIBITORS - A method comprising co-administering to a subject having cancer, suspected of having cancer, or at risk of developing cancer:
| 2022-02-10 |
20220040135 | THERAPEUTIC COMPOSITIONS OF DECANOIC ACID AND ARGININE - Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. In particular, described herein are compositions of decanoic acid: Arginine in which the decanoic acid and Arginine for a complex having a lamellar supramolecular structure. | 2022-02-10 |
20220040136 | TREATMENT OF VULVOVAGINAL DISORDERS - The present invention relates to methods of treating vulvovaginal disorders, including female reproductive tract irritation (such as pain and pruritus) or/and inflammation. | 2022-02-10 |
20220040137 | ANTIVIRAL TREATMENTS - The invention provides unit dosage forms, kits, and methods useful for treating viral infections. | 2022-02-10 |
20220040138 | TERIFLUNOMIDE TOPICAL PHARMACEUTICAL COMPOSITIONS - The present invention relates to a novel topical pharmaceutical composition of Teriflunomide, comprising teriflunomide or its pharmaceutically acceptable salt in combination with pharmaceutically acceptable excipients, wherein the said composition is effective for use in treatment of pain associated with disorders like inflammation and arthritis. The composition is also useful for relieving the symptoms of pain and arthritis in subjects suffering from autoimmune diseases like multiple sclerosis or rheumatoid arthritis. The said topical composition of teriflunomide is prepared in the form of topical gel, topical cream, topical ointment, topical solution, lotion or topical spray with significantly enhanced permeability and diffusion rate of the drug. | 2022-02-10 |
20220040139 | HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKER AND USES THEREOF - The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia. | 2022-02-10 |
20220040140 | METHOD OF IMPROVING SLEEP - The invention provides methods of improving sleep in a patient having a variant of the cryptochrome circadian clock 1 (CRY 1) genotype associated with a circadian rhythm sleep disorder (CRSD) Delayed Sleep Wake Phase Disorder (DSWPD). | 2022-02-10 |
20220040141 | ULTRAPURE PHENOL COMPOSITIONS - A composition can include a cannabinoid and caprylic acid triglyceride. | 2022-02-10 |
20220040142 | PHARMACEUTICAL APPLICATION FOR THE INHIBITION OF NOVEL CORONAVIRUSES BY MYRICETIN - The present disclosure provides a pharmaceutical application for the inhibition of novel coronaviruses by myricetin, which was shown to bind the 2019-nCoV-M | 2022-02-10 |
20220040143 | COMBINATION MAST CELL INHIBITION FOR TREATMENT OF BPH/LUTS - Provided herein are compositions and methods for the treatment of conditions such as benign prostatic hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS), chronic prostatitis (CP) and/or chronic pelvic pain syndrome (CPPS). In particular, provided herein are combination therapies comprising a mast cell inhibitor and a histamine receptor antagonist. | 2022-02-10 |
20220040144 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CUTANEOUS T CELL LYMPHOMA (CTCL) - Compositions and methods for the treatment of cutaneous T cell lymphoma (CTCL) are provided. The compositions and uses thereof comprise cannabinoids. | 2022-02-10 |
20220040145 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID - The present disclosure provides methods and compositions for the prevention, amelioration, or alleviation of one or more neurological disorders associated with microbially-induced amyloid formation. Methods of inhibiting, ameliorating, reducing the likelihood, delaying the onset of, treating, or preventing an amyloid disorder are disclosed. Methods of identifying compounds capable of inhibiting the formation of microbially-induced amyloid fibrils are disclosed. | 2022-02-10 |
20220040146 | ANTIMICROBIAL COMPOSITIONS AND RELATED METHODS - A pharmaceutical composition is provided that comprises an effective amount of dillapiole or a derivative thereof, and a pharmaceutically-acceptable vehicle, carrier, or excipient. Methods of treating a bacterial infection are also described and include administering an effective amount of dillapiole or a derivative thereof to a subject in need of such treatment. Methods of reducing bacterial virulence are further described and include contacting a bacterium, such as a | 2022-02-10 |
20220040147 | SHORT SYNTHESES OF (-)-PICROTOXININ AND RELATED COMPOUNDS - The present disclosure relates to concise processes for making (−)-picrotoxinin (1, PXN) and 5-methyl-picrotoxinin (20, 5MePXN), and to 5MePXN, its pharmaceutical compositions, and its method of use for inhibiting GABA | 2022-02-10 |
20220040148 | COMBINATION DRUG FORMULATIONS INCLUDING ROTIGOTINE AND AN ACETYLCHOLINESTERASE INHIBITOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - This disclosure relates to the pharmacological treatment of apathy and loss of executive function in treatment of neurodegenerative diseases by administration of a combination drug formulation including rotigotine and an acetylcholinesterase inhibitor. | 2022-02-10 |
20220040149 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS - Disclosed are combination therapies including administration of I-DASH inhibitors and PGE2 antagonists, and the use of such therapies in the treatment of cell proliferative diseases. | 2022-02-10 |
20220040150 | INTRAVENOUS DMT ADMINISTRATION METHOD FOR DMT-ASSISTED PSYCHOTHERAPY - A method of inducing a psychedelic state in an individual by administering DMT, a salt of DMT, analogs thereof, or derivatives thereof to an individual with a continuous perfusion system and inducing a psychedelic state. A method of inducing a psychedelic state in an individual safely, by administering DMT, a salt of DMT, analogs thereof, or derivatives thereof to an individual with a continuous perfusion system, inducing a psychedelic state, and adjusting or ending the psychedelic state on demand. A method of providing a short lasting psychedelic treatment of minutes to 1-2 hours, by administering DMT, a salt of DMT, analogs thereof, or derivatives thereof to an individual with a continuous perfusion system and providing psychedelic treatment for minutes to 1-2 hours. A method of determining a dose of DMT for an individual. | 2022-02-10 |
20220040152 | COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA, MILD HYPEROPIA, AND IRREGULAR ASTIGMATISM - The present invention is directed to compositions and methods for treating ocular conditions, including presbyopia, mild hyperopia, irregular astigmatism, hyperopic accommodative esotropia, and glaucoma. The compositions can also be used to potentiate or enhance interventions that retard, reverse, or modify the aging process of the crystalline lens and its surrounding tissues. The compositions include a cholinergic agent, such as a muscarinic acetylcholine receptor M | 2022-02-10 |
20220040153 | METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES - Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents. | 2022-02-10 |
20220040154 | USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA - Disclosed herein are methods of treating moderate to severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 75 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof, and treating severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 150 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof. | 2022-02-10 |
20220040155 | METHODS OF TREATING TUBEROUS SCLEROSIS COMPLEX WITH CANNABIDIOL AND EVEROLIMUS - The present disclosure provides methods of treating tuberous sclerosis complex comprising administering cannabidiol and everolimus. | 2022-02-10 |
20220040156 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING OBSESSIVE-COMPULSIVE DISORDER - In alternative embodiments, provided are pharmaceutical compositions and methods for treating, ameliorating, reversing and/or preventing (acting as a prophylaxis) an Obsessive-Compulsive Disorder (OCD), with or without an accompanying autism or an autism spectrum disorder (ASD), e.g., a regressive autism. In alternative embodiments, these pharmaceutical compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, pharmaceutical compositions and methods are dosaged, formulated and dosaged as solid, liquid or aerosol preparations or formulations. In alternative embodiments, pharmaceutical compositions comprise rifaximin as the sole antibiotic, or rixafimin and other antimicrobial or antibiotic agent, for example, vancomycin, metronidazole, tinidazole, secnidazole or a combination thereof. As there are various molecular forms of rifaximins, all these are useful and used in methods and compositions as provided herein | 2022-02-10 |
20220040157 | SOLID DISPERSION FORMS OF RIFAXIMIN - Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof. | 2022-02-10 |
20220040158 | AZD0328 DOSAGE REGIME FOR TREATING COGNITIVE IMPAIRMENT - The nicotinic acetylcholine receptor alpha 7 (□7 nAChR) agonist ((3R)-Spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of mild cognitive impairment (MCI) in Parkinson's disease, wherein the compound is administered in a unit dose of from 0.25 mg to 0.50 mg twice daily. Methods of treatment or prophylaxis of MCI and kits for use in the such methods are also provided. | 2022-02-10 |
20220040159 | SOLID FORMS OF {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC ACID, COMPOSITIONS, AND USES THEREOF - Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders. | 2022-02-10 |
20220040160 | COMBINATION OF HISTONE DEACETYLASE INHIBITOR AND IMMUNOTHERAPY - A method of reducing cancer cell growth, a method of increasing sensitivity of cancer cells to CTL mediated killing, and a method of increasing sensitivity of cancer cells to NK mediated killing are provided. The methods comprise treating cancer cells with a combination of a HDAC inhibitor and immunotherapy. | 2022-02-10 |
20220040161 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 2022-02-10 |
20220040162 | COMPOSITIONS COMPRISING A CRAC INHIBITOR AND A CORTICOSTEROID AND METHODS OF USE THEREOF - The present disclosure relates to a method of treating an autoimmune, respiratory and/or inflammatory disease or condition (such as psoriasis, rheumatoid arthritis, asthma, or COPD) by administering at least one calcium release-activated calcium (CRAC) modulator (such as a CRAC inhibitor) and at least one corticosteroid. | 2022-02-10 |
20220040163 | SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF - The present application relates generally to compounds useful for the treatment and/or enhancement of cognitive dysfunction and negative symptoms associated with CNS disorders where the circuitry involving fast spiking PV+ interneurons and the production of cortical gamma oscillations is disrupted. The subject disclosure enables the manufacture of medicaments as well as compositions containing same for use in methods of therapy and prophylaxis of cognitive dysfunction and negative symptoms. | 2022-02-10 |
20220040164 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF - The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same. | 2022-02-10 |
20220040165 | 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-t- riazol-3-yl]pyridine . . . . - The present invention relates to 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00), or a pharmaceutically acceptable salt thereof, diastereomer, enantiomer, isotope, pro-drug or metabolite or mixture thereof, or a pharmaceutical composition comprising said TT00, for use in prevention and/or treatment of pain, such as chronic and/or peripheral pain and/or pain related to arthritis, such as osteoarthritis, or for use in prevention and/or treatment of said pain combined with b) GERD or c) anxiety in animals, such as dogs, cats or horses. | 2022-02-10 |
20220040166 | Methods and Compositions of Treating an Ophthalmic Condition - Therapeutic methods and pharmaceutical compositions for treating an ophthalmic condition including age-related macular degeneration in a human subject are described. In certain embodiments, the invention includes therapeutic methods using an MDM2 inhibitor. | 2022-02-10 |
20220040167 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders. | 2022-02-10 |
20220040168 | TREATMENT OF HEPATOCELLULAR CARCINOMA - This disclosure provides methods for treating a hepatocellular carcinoma (e.g., unresectable HCC) with lenvatinib or a pharmaceutically acceptable salt thereof. Also encompassed by the disclosure are dosage regimens described herein of lenvatinib or a pharmaceutically acceptable salt thereof for use in treating hepatocellular carcinoma (e.g., unresectable hepatocellular carcinoma) according to any of the methods described herein. Particularly useful dosages and dose modifications upon the occurrence of an adverse event or events are also disclosed. | 2022-02-10 |
20220040169 | Methods for the Administration of Certain VMAT2 Inhibitors - Provided is a method of administering a vesicular monoamine transport 2 (VMAT2) inhibitor to a patient in need thereof, wherein the patient experiences one or more clinically significant parkinson-like signs or symptoms. | 2022-02-10 |
20220040170 | ANALOGS OF DEUTETRABENAZINE, THEIR PREPARATION AND USE - The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine. | 2022-02-10 |
20220040171 | METHOD FOR TREATMENT OF CYTOKINE RELEASE SYNDROME - A composition for preventing and/or treating cytokine release syndrome and a method of prevention and/or treatment of cytokine release syndrome are disclosed. The composition includes an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof. The cytokine release syndrome may be caused by virulent infection. The administration of the compound reduces the pre-inflammatory cytokine levels in the subject. | 2022-02-10 |
20220040172 | TREATMENT FOR NON-ALCOHOLIC FATTY LIVER DISEASE - The invention provides novel methods of treating or preventing nonalcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH) in a mammal including a human. | 2022-02-10 |
20220040173 | METHODS OF DELAYING PAIN PROGRESSION AND TREATING PROSTATE CANCER - This disclosure relates to methods for delaying pain progression in a subject receiving treatment for prostate cancer. This disclosure further relates to methods for treating prostate cancer, such as for example, treating prostate cancer in a subject having pain. | 2022-02-10 |
20220040174 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction - The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes. | 2022-02-10 |
20220040175 | INFIGRATINIB FOR TREATMENT OF FGFR3-RELATED SKELETAL DISEASES DURING PREGNANCY - FGFR3 gain-of-function mutations are responsible for a family of chondrodysplasias namely, achondroplasia (ACH) the most common form of dwarfism, a lethal form of dwarfism thanatophoric dysplasia (TD) as well as and hypochondroplasia. Recent data demonstrate that Infigratinib (NVP-BGJ398) corrects pathological hallmarks of ACH and support it as a 10 potential therapeutic approach for FGFR3-related skeletal diseases. Now the inventors has investigated the feasibility to treat the defective growth of the skeleton during the pregnancy with the drug. They treated pregnant female Fgfr3 | 2022-02-10 |
20220040176 | C-TERMINAL SRC KINASE INHIBITORS - Provided herein are novel C-terminal Srk Kinase (CSK) inhibitors, e.g., having Formula G, I, II, or III. Also provided are methods of preparing the novel CSK inhibitors and method of using the novel CSK inhibitors for treating diseases or disorder such as cancer or for promoting immune response in a subject in need thereof. (G) | 2022-02-10 |
20220040177 | Compounds, Compositions and Methods of Treating or Preventing Acute Lung Injury - The invention includes methods of preventing or treating acute lung injury using a MAP3K2/MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention. | 2022-02-10 |
20220040178 | COMBINATION THERAPY OF HBV AND HDV INFECTION - The invention provides a composition comprising an inhibitor of Na+-taurocholate cotransporting polypeptide (NTCP) and a active ingredient selected from the group consisting of a nucleoside analogue such as lamivudine, telbivudine, or entecavir, a nucleotide analogue such as tenofovir, adefovir and an immunomodulator such as interferon alpha. The NTCP inhibitor inhibits HBV/HDV entry into a cell and is preferably derived from an HBV pre-S1 peptide. Also provided are methods of treating HBV and HDV infection, hepatitis B and D, or chronic hepatitis B and D. | 2022-02-10 |
20220040179 | USE OF CDK8/19 INHIBITORS FOR TREATMENT OF ESTABLISHED COLON CANCER HEPATIC METASTASIS - The invention relates to the treatment of cancer. More particularly, the invention relates to the treatment of metastatic cancer. The invention provides new treatments for colon cancer patients who develop metastasis in the liver. The invention provides a method for treating hepatic metastatic colon cancer in a subject, the method comprising administering to the subject a small molecule selective inhibitor of CDK8/19 at a dosage that inhibits growth of the hepatic metastatic colon cancer, and does not cause a dose-limiting toxicity. The invention further provides a method for treating a subject having both a primary colon cancer tumor and hepatic metastatic colon cancer, the method comprising administering to the subject a small molecule selective inhibitor of CDK8/19 at a dosage that inhibits growth of the hepatic metastatic colon cancer, but does not significantly inhibit growth of the primary colon cancer tumor. | 2022-02-10 |
20220040180 | KITS AND METHODS FOR TREATING CANCERS - A kit containing a crystalline form of a quinazoline compound. More particularly, the crystalline form is derived from the compound of 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one. Also disclosed is a method of treating cancers with the crystalline form or a kit thereof. | 2022-02-10 |
20220040181 | COMBINATION THERAPIES - The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Src-family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor. | 2022-02-10 |
20220040182 | COMBINATION THERAPIES - The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a mTOR inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor. | 2022-02-10 |
20220040183 | USE OF INHIBITORS OF STRESS GRANULE FORMATION FOR TARGETING THE REGULATION OF IMMUNE RESPONSES - The mechanisms of tumor escape are numerous, but the immunosuppressive action of coinhibitory molecules has emerged this last decade as the most attractive one for imaging new treatments of cancer. Activation of lymphocytes is indeed regulated by both costimulatory and coinhibitory molecules also called “immune checkpoints”. Now the inventors show that T cell activation triggers mRNA and protein expression of stress granule components and more particularly show that immune checkpoint mRNA interact with said stress granules. More importantly, stress granule inhibitors impair expression of immune checkpoint and thus represent an attractive target for targeting the regulation of immune response. | 2022-02-10 |
20220040184 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE - In its many embodiments, the present invention provides certain substituted amino triazolopyrimidine and amino triazolopyrazine compounds of Formula (IA) and Formula (IB): and, and pharmaceutically acceptable salts thereof, wherein, R | 2022-02-10 |
20220040185 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION - Compounds, compositions, and methods of treatment and prevention of HIV, including HIV-1 and HIV-2, Dengue, and Chikungunya infection are disclosed. The compounds are TREM-1 inhibitors. Combinations of these TREM-1 inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, JAK inhibitors, macrophage depleting agents, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV, Dengue, or Chikungunya virus in an infected patient. | 2022-02-10 |
20220040186 | COMPOSITIONS AND METHODS OF TREATMENT FOR NEUROLOGICAL DISORDERS COMPRISING DEPRESSION - This invention, in at least some embodiments, relates to an inventive molecule, compositions comprising same, and methods of use thereof for treatment of a neurological disorder. | 2022-02-10 |
20220040187 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS - This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES). | 2022-02-10 |
20220040188 | METHODS OF TREATING HEMATOLOGIC CANCERS - The present application relates to treatment of hematologic cancers, which treatments can include, e.g., administration of a purine nucleoside phosphorylase (PNP) inhibitor, an alkylating agent and/or an anti-CD20 agent, and related compositions and kits. | 2022-02-10 |
20220040189 | COMPOSITIONS AND METHODS OF TREATMENT FOR NEUROLOGICAL DISORDERS COMPRISING MOTOR NEURON DISEASES - This invention, in at least some embodiments, relates to an inventive molecule, compositions comprising same, and methods of use thereof for treatment of a neurological disorder. | 2022-02-10 |
20220040190 | Methods and Compositions for Inhibition of Polymerase - The present invention is directed to methods and compositions for inhibition of viral nucleic acid polymerases, such as RNA and DNA polymerases, and methods and compositions that are useful for treating viral infections in subjects. The methods comprise administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The composition or method may optionally comprise one or more additional anti-viral agents. | 2022-02-10 |
20220040191 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES - In an embodiment of the invention, a method of treating cancer includes screening to select a patient population that will respond to an Illudofulvene Analog composition based on the presence of one or more Transcription Coupled Repair (TCR) mutations, deletions or other events interfering with TCR biomarker expression in combination with upregulation of Myc and/or PTGR biomarker expression and treating the patient population with the Illudofulvene Analog composition. | 2022-02-10 |
20220040192 | IMMUNOPROTEASOME INHIBITOR FORMULATIONS - Provided herein are pharmaceutical formulations comprising KZR-616 or a salt thereof, and a sugar, wherein the formulations are lyophilized, methods of preparing said formulations, methods of treating immune-related diseases, and methods of treating inflammation. | 2022-02-10 |
20220040193 | FORMULATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS - The present disclosure provides formulations suitable for topical administration that include compounds of formula (I): | 2022-02-10 |
20220040194 | USE OF OLANZAPINE FOR TREATMENT OF PARP-INHIBITOR-INDUCED NAUSEA - The present invention generally relates to a combination therapy of a PARP-inhibitor and olanzapine. More particularly, embodiments relate to a method of administering to a patient one or more of a PARP-inhibitor in a therapeutic amount to a patient in need thereof, and olanzapine, in a sufficient amount to treat or alleviate PARP-inhibitor induced nausea or vomiting. In embodiments, the PARP-inhibitor and olanzapine are administered in a common administration schedule. In some embodiments, both actives are orally administered. In other embodiments, olanzapine is transdermally administered. In certain embodiments, the PARP-inhibitor is one or more of olaparib, rucaparib, and niraparib. | 2022-02-10 |
20220040195 | USE OF VANADIUM COMPOUNDS FOR MAINTAINING NORMAGLYCEMIA IN A MAMMAL - The present invention relates to a method for maintaining normoglycemia in a mammal in need thereof, preferably a critically ill patient suffering from acute stress, and to a method for preventing or limiting renal ischemia-reperfusion (I/R) in a mammal, preferably in a critically ill patient suffering from acute stress. | 2022-02-10 |
20220040196 | Pharmaceutical Composition of Chlordiazepoxide and Clidinium Combination - The present invention relates to a stable pharmaceutical composition comprising a combination of chlordiazepoxide hydrochloride and clidinium bromide and one or more pharmaceutically acceptable excipients, wherein the composition is in the form of solid oral dosage forms like capsule and sachet. The technical challenges like undesirable impurities in dosage form were successfully controlled by using: a) low moisture excipients; and b) formulation development under controlled temperature and controlled humidity conditions. The formulations as per the present invention are stable and exhibit desired pharmaceutical technical attributes like assay and dissolution. The prepared formulations are useful for the treatment of gastrointestinal disorders and various other therapeutic indications as described herein. | 2022-02-10 |
20220040197 | COMPOSITIONS AND METHODS OF TREATMENT FOR NEUROLOGICAL DISORDERS COMPRISING A DEMENTIA - This invention, in at least some embodiments, relates to an inventive molecule, compositions comprising same, and methods of use thereof for treatment of a neurological disorder. | 2022-02-10 |
20220040198 | COMPOSITIONS COMPRISING SHORT-ACTING BENZODIAZEPINES - The present invention provides novel compositions comprising benzodiazepine derivatives according to formula (I). Also provided are compositions comprising at least one hygroscopic excipient, in particular lactose and/or dextran. | 2022-02-10 |
20220040199 | 9,11-SECOSTEROIDS AND THE USE OF 9,11-SECOSTEROIDS IN PREPARING PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INFLAMMATION - A method for inhibiting inflammatory in a subject is provided, comprising: administering a pharmaceutical composition comprising an effective amount of 9,11-secosteroids. | 2022-02-10 |
20220040200 | ETHINYL ESTRADIOL- -CYCLODEXTRIN COMPLEX AND PROCESS FOR PREPARING THEREOF - The process comprises combining prepared β-cyclodextrin solution and prepared ethinyl estradiol solution, then removing the solvent by spray-drying for obtaining an ethinyl estradiol β-cyclodextrin complex. The obtainable amorphous ethinyl estradiol β-cyclodextrin complex is suitable for use in pharmaceutical compositions and formulations comprising it. | 2022-02-10 |
20220040201 | LIQUID POLYMER DELIVERY SYSTEM FOR EXTENDED ADMINISTRATION OF DRUGS - Liquid polymer pharmaceutical compositions comprising a biodegradable liquid polymer, a biocompatible solvent system, and an active pharmaceutical ingredient (API) are disclosed. The compositions of the invention are useful for providing extended, long-term release of the API. | 2022-02-10 |
20220040202 | INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS - The present disclosure provides for methods of treating or preventing a cardiovascular disorder and/or a related pulmonary disorder in a subject. In certain embodiments, the method comprises administering a therapeutically effective amount of an inhibitor of Glucose-6-phosphate dehydrogenase (G6PD), or a pharmaceutically acceptable salt, non-salt amorphous form, solvate, poly-morph, tautomer or prodrug thereof. | 2022-02-10 |
20220040203 | LIQUID FORMULATION COMPOSITIONS, MEDICAMENT DELIVERY DEVICES, AND METHODS OF PREPARATION AND USE THEREOF - The invention provides liquid formulation compositions and medicament delivery devices, and methods for preparing and using the same. For example, the liquid formulation composition is an emulsion including a solvent and liquid particles, which includes surfactants and are dispersed in the solvent. The volume average particle size of the liquid particles is less than about 100 μm; the surface tension of the liquid formulation composition is less than about 60 mN/m; and the absolute value of zeta potential is greater than about 15 mV. The containment vessel may be a sprayer or a dropping device. The invention also provides methods for preparation of the liquid formulation compositions and medicament delivery devices as well as methods for using the same in treatment of various diseases and condition, for example, otitis media, otitis externa, rhinitis, sinusitis, lower respiratory tract inflammation, xerostomia (dry mouth), xerophthalmia (dry eyes) and xeromycteria (dry nose). | 2022-02-10 |
20220040204 | LOW DOSE COMPOSITIONS OF ARAMCHOL SALTS - The present invention relates to salts of arachidyl amido cholanoic acid (Aramchol), pharmaceutical compositions comprising Aramchol salts, methods for their preparation, and methods of use thereof in medical treatment. | 2022-02-10 |
20220040205 | STABILITY OF VITAMIN D IN BETA-HYDROXY- BETA-METHYLBUTYRATE (HMB) - The present invention provides a composition comprising an acidic formulation containing β-hydroxy-β-methylbutyrate (HMB), preferably in the free acid form, Vitamin D and a stabilizing excipient, wherein the Vitamin D is stabilized against degradation. | 2022-02-10 |
20220040206 | DRY POWDER FORMULATIONS FOR INHALATION - A respirable dry powder can include acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) within a range of about 0.5 μm to about 10 μm. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as an amino acid (e.g., Leucine), in an amount ranging from about 0.1% (w/w) to about 40% (w/w) of the particles. | 2022-02-10 |
20220040207 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA - Disclosed herein is a class of molecules termed remodilins that inhibit serum response factor (SRF). By inhibiting SRF, a number of downstream pathways can be targeted. The remodilins can be used to treat glaucoma, inhibit tumor cell growth, inhibit tumor metastasis, inhibit hypoxia-induced response, and/or reduce cellular metabolism. | 2022-02-10 |
20220040208 | Modified Tetracycline for Treatment of Alcohol Use Disorder, Pain and Other Disorders Involving Potential Inflammatory Processes - A method of treating Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: providing a subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate or eliminate the AUD, SUD, tobacco use, pain, or proinflammatory disorder, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula wherein R1 is acetyl, R2 is OH or acetyl, R3 is acetyl, R4 is H or acetyl, and R5 is acetyl. | 2022-02-10 |
20220040209 | SELF-EMULSIFYING FORMULATION OF BISPHOSPHONATES AND ASSOCIATED DOSAGE FORMS - The patent discloses self-emulsifying formulations of bisphosphonates or bisphosphonic acids in the prevention and treatment of conditions involving calcium or phosphate metabolism. The dosage forms are either capsules, or tablets, or other controlled release drug delivery systems, or devices that contain self-emulsifying formulation of such bisphosphonates or bisphosphonic acids. | 2022-02-10 |
20220040210 | CARBORANE COMPOUNDS, CARBORANE ANALOGS, AND METHODS OF USE THEREOF - Disclosed are method of treating fibrotic conditions using carboranes and carborane analogs. Also disclosed herein are compounds comprising dicarba-closo-dodecaborane or a dicarba-closo-dodecaborane analog. The compounds can be, for example, estrogen receptor beta (ERβ) agonists. In some examples, the compounds can be selective ERβ agonists. Also provided herein are methods of treating, preventing, or ameliorating cancer in a subject, suppressing tumor growth in a subject, treating an inflammatory disease in a subject, treating a neurodegenerative disease in a subject, treating a psychotropic disorder in a subject, or a combination thereof, by administering to a subject a therapeutically effective amount of one or more of the compounds or compositions described herein, or a pharmaceutically acceptable salt thereof. | 2022-02-10 |
20220040211 | Dietary fiber for treating patients suffering from methylmalonic acidemia and propionic acidemia - The present invention concerns a composition comprising dietary fiber for use in the dietary management of methylmalonic acidemia (MMA) and/or propionic acidemia (PA), and/or for use in treating and/or reducing MMA and/or PA, and/or treating, reducing and/or preventing symptoms associated therewith. | 2022-02-10 |